1 Growth Stock Down 19% to Buy Right Now

Last year was not a good one for Dexcom (NASDAQ: DXCM). The medical device specialist lagged the market, and even with a bit of a rebound toward the second half of 2025, shares are down 19% over the trailing-12-month period. However, there are still great reasons to consider investing in Dexcom.Let's see why the healthcare company could be a great buy.Dexcom is a medical device specialist that manufactures and markets continuous glucose monitoring (CGM) devices, which help diabetes patients track their blood sugar levels throughout the day. Last year, the company faced the ire of regulators and complaints from some of its customers because some of its CGM receivers were defective. The receivers' speakers malfunctioned and failed to audibly alert patients of critically low (or high) blood sugar. Dexcom faced a Class 1 recall for 602,445 of its G7 receivers.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool